1997
DOI: 10.1128/iai.65.6.2272-2277.1997
|View full text |Cite
|
Sign up to set email alerts
|

Saturable CD14-dependent binding of fluorescein-labeled lipopolysaccharide to human monocytes

Abstract: We used rough lipopolysaccharide (ReLPS) to construct a fluorescein-labeled LPS (FITC-LPS) with a very high labeling efficiency that bound to isolated human monocytes in a CD14-dependent fashion and that in this respect behaved indistinctively from native LPS. The CD14-dependent binding could be inhibited either by a 1,000-fold excess of unlabeled LPS or by polymyxin B, bactericidal/permeability-increasing protein, cationic protein 18, or soluble CD14. Although this FITC-LPS preparation no longer possessed the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
30
0

Year Published

2000
2000
2014
2014

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 55 publications
(31 citation statements)
references
References 42 publications
1
30
0
Order By: Relevance
“…The latter hypothesis remains however, unlikely because LBP is not required when LPS is used at high doses. 50 The inability of Hp to act at low doses may reflect its neutral role in the immune system under normal physiological conditions. However, the initiation of an inflammatory process will increase Hp synthesis by the liver, and Hp might then exhibit its anti-inflammatory potential to slow down the inflammation.…”
Section: Discussionmentioning
confidence: 99%
“…The latter hypothesis remains however, unlikely because LBP is not required when LPS is used at high doses. 50 The inability of Hp to act at low doses may reflect its neutral role in the immune system under normal physiological conditions. However, the initiation of an inflammatory process will increase Hp synthesis by the liver, and Hp might then exhibit its anti-inflammatory potential to slow down the inflammation.…”
Section: Discussionmentioning
confidence: 99%
“…The binding characteristics of LPS to CD14 were studied by several authors, defining the CD14-dependent binding with blocking anti-CD14 mAbs or comparing binding in the presence and absence of excess LBP or serum [52,53,62,63]. CD14-mediated binding of E. coli K12 LCD25 Ra or Rb LPS to CD14-transfected CHO cells or to differentiated THP-1 cells showed saturation at 100-500 ng mL ¹1 (about 25 nM) endotoxin with a binding affinity of K D ¼ 10-50 nM and with a CD14 to LPS binding ratio of 1-2, 10-20 or 15 LPS molecules per CD14 [31,53,55,[62][63][64]. According to the most recent model, CD14 forms a ternary complex with LPS and LBP, and not only monomeric but multiple LPS-LBP complexes might bind to CD14.…”
Section: Mcd14 Is the Lps 'Receptor'mentioning
confidence: 99%
“…To study the internalization rate and mechanisms of CD14-bound endotoxin on human monocytes, 10 ng/ml FITC-LPS was incubated with 1% NHS and 10 6 mononu-clear cells for 10 min at 37°C. These conditions ensure a totally CD14-dependent binding of LPS to the monocytes (32). The nonbound FITC-LPS was removed and the cells were further incubated for 0, 5, 10, 15, 30, and 60 min to facilitate the internalization of surface-bound endotoxin.…”
Section: Internalization Of Fitc-lps Is Not Accompanied By a Decreasementioning
confidence: 99%